(0.34%) 5 117.37 points
(0.31%) 38 360 points
(0.38%) 15 988 points
(-0.86%) $83.13
(5.82%) $2.04
(0.43%) $2 357.40
(0.48%) $27.67
(3.93%) $958.35
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
@ $3.64
発行日: 14 2月 2024 @ 05:55
リターン: -11.69%
前回のシグナル: 2月 10 - 03:51
前回のシグナル:
リターン: -3.84 %
Live Chart Being Loaded With Signals
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders...
Stats | |
---|---|
本日の出来高 | 78 557.00 |
平均出来高 | 490 846 |
時価総額 | 186.00M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-0.560 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.150 |
ATR14 | $0.00600 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-17 | Demopulos Gregory A Md | Buy | 15 000 | Common Stock |
2023-11-15 | Demopulos Peter A Md | Buy | 10 000 | Common Stock |
2023-11-14 | Demopulos Gregory A Md | Buy | 25 000 | Common Stock |
2023-11-13 | Demopulos Gregory A Md | Buy | 37 500 | Common Stock |
2023-09-22 | Demopulos Gregory A Md | Buy | 715 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
97.84 |
Last 99 transactions |
Buy: 3 182 539 | Sell: 554 578 |
ボリューム 相関
Omeros Corp 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Omeros Corp 相関 - 通貨/商品
Omeros Corp 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
収益: | $0 |
総利益: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2022 |
収益: | $0 |
総利益: | $-952 000 (0.00 %) |
EPS: | $0.460 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $3.12 |
Financial Reports:
No articles found.
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。